3-Year Follow-Up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) Trial

被引：46

作者：

Holmes, David R., Jr. ^{[1
]}

Teirstein, Paul S. ^{[2
]}

Satler, Lowell ^{[3
]}

Sketch, Michael H., Jr. ^{[4
]}

Popma, Jeffery J. ^{[5
]}

Mauri, Laura ^{[5
]}

Wang, Hong ^{[6
]}

Schleckser, Patricia A. ^{[6
]}

Cohen, Sidney A. ^{[6
]}

机构：

[1] Mayo Clin, Dept Cardiol, Rochester, MN 55905 USA

[2] Scripps Mem Hosp, La Jolla, CA USA

[3] Washington Hosp Ctr, Washington, DC 20010 USA

[4] Duke Univ, Med Ctr, Durham, NC USA

[5] Brigham & Womens Hosp, Boston, MA 02115 USA

[6] Cordis Corp, Warren, NJ USA

来源：

JACC-CARDIOVASCULAR INTERVENTIONS | 2008年 / 1卷 / 04期

关键词：

bare-metal stent restenosis; vascular brachytherapy; Cypher stent;

D O I：

10.1016/j.jcin.2008.05.010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives The aim of this study was to evaluate long-term outcome of patients treated for in-stent restenosis of bare-metal stents (BMS). Background Treatment of restenosis of BMS is characterized by high recurrence rates. Vascular brachytherapy (VBT) improved outcome although late catch-up events were documented. Drug-eluting stents tested against VBT in this setting were found superior for at least the first year; superiority at longer follow-up is uncertain. Methods We evaluated 3-year outcome of the multicenter SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial, which randomized patients with restenosis of BMS to either a sirolimus-eluting stents (SES) or VBT. Results Target vessel failure (cardiac death, infarction, or target vessel revascularization [TVR]) at 9 months as previously reported was significantly improved with SES. Kaplan-Meier analysis at 3 years documented that survival free from target lesion revascularization (TLR) and TVR continues to be significantly improved with SES: freedom from TLR 81.0% versus 71.6% (log-rank p = 0.018), and TVR 78.2% versus 68.8% (log-rank p = 0.022), SES versus VBT. At 3 years, target vessel failure and major adverse cardiac events (death, infarction, emergency coronary artery bypass grafting, or repeat TLR) remained improved with SES, but did not reach statistical significance. There was no statistically significant difference in definite or probable stent thrombosis (3.5% for SES, 2.4% for VBT; p = 0.758). Conclusions At 3 years of follow-up, after treatment of in-stent restenosis of BMS, patients treated with SES have improved survival free of TLR and TVR compared with patients treated with VBT. Stent thrombosis rates are not different between the 2 groups but are higher than reported in trials of treatment of de novo lesions. (J Am Coll Cardiol Intv 2008;1:439-48) (C) 2008 by the American College of Cardiology Foundation

引用

页码：439 / 448

页数：10

共 39 条

[1] Late thrombosis of drug-eluting stents: A meta-analysis of randomized clinical trials [J].

Bavry, Anthony A. ;

Kumbhani, Dharam J. ;

Helton, Thomas J. ;

Borek, Przemyslaw P. ;

Mood, Girish R. ;

Bhatt, Deepak L. .

AMERICAN JOURNAL OF MEDICINE, 2006, 119 (12) :1056-1061

[2] Use of sirolimus-eluting stents for treatment of in-stent restenosis: long-term follow-up [J].

Brambilla, Nedy ;

Ferrario, Maurizio ;

Repetto, Alessandra ;

Bramucci, Ezio ;

Angoli, Luigi ;

Canosi, Umberto ;

Rosso, Roberta ;

Ferlini, Marco ;

Klersy, Catherine ;

Tavazzi, Luigi .

JOURNAL OF CARDIOVASCULAR MEDICINE, 2007, 8 (09) :699-705

[3]

Brunner-La Rocca HP, 2007, LANCET, V370, P1552

[4] Stent thrombosis late after implantation of first-generation drug-eluting stents - A cause for concern [J].

Camenzind, Edoardo ;

Steg, P. Gabriel ;

Wijns, William .

CIRCULATION, 2007, 115 (11) :1440-1455

[5] Bare metal stent restenosis is not a benign clinical entity [J].

Chen, Michael S. ;

John, Jim M. ;

Chew, Derek P. ;

Lee, David S. ;

Ellis, Stephen G. ;

Bhatt, Deepak L. .

AMERICAN HEART JOURNAL, 2006, 151 (06) :1260-1264

[6] ISR II study:: A long-term evaluation of sirolimus-eluting stent in the treatment of patients with in-stent restenotic native coronary artery lesions [J].

Commeau, P ;

Barragan, PT ;

Roquebert, PO ;

Siméoni, JB .

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2005, 66 (02) :158-162

[7] Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents [J].

Doyle, Brendan ;

Rihal, Charanjit S. ;

O'Sullivan, Crochan J. ;

Lennon, Ryan J. ;

Wiste, Heather J. ;

Bell, Malcolm ;

Bresnahan, John ;

Holmes, David R., Jr. .

CIRCULATION, 2007, 116 (21) :2391-2398

[8] Prevention of premature ditscontinuation of dual antiplatelet therapy in patients with coronary artery stents [J].

Grines, Cindy L. ;

Bonow, Robert O. ;

Casey, Donald E., Jr. ;

Gardner, Timothy J. ;

Lockhart, Peter B. ;

Moliterno, David J. ;

O'Gara, Patrick ;

Whitlow, Patrick .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (06) :734-739

[9] Five-year clinical follow-up after intracoronary radiation - Results of a randomized clinical trial [J].

Grise, MA ;

Massullo, V ;

Jani, S ;

Popma, JJ ;

Russo, RJ ;

Schatz, RA ;

Guarneri, EM ;

Steuterman, S ;

Cloutier, DA ;

Leon, MB ;

Tripuraneni, P ;

Teirstein, PS .

CIRCULATION, 2002, 105 (23) :2737-2740

[10] Thrombosis and drug-eluting stents - An objective appraisal [J].

Holmes, David R., Jr. ;

Kereiakes, Dean J. ;

Laskey, Warren K. ;

Colombo, Antonio ;

Ellis, Stephen G. ;

Henry, Timothy D. ;

Popma, Jeffrey J. ;

Serruys, Patrick W. J. C. ;

Kimura, Takeshi ;

Williams, David O. ;

Windecker, Stephan ;

KrucofF, Mitchell W. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (02) :109-118

← 1 2 3 4 →